Active and Upcoming Projects
Mobile health technologies for smoking cessation, mental health, and health disparities in diverse populations.
Smart-T Mental Health
Pilot trial testing a smoking cessation app for serious mental illness
OKquit
Clinical trial on tailored smoking cessation app for Oklahoma helpline users
MASP 3.0
Mobile intervention addressing health disparities among African American smokers
CT-MICART
Culturally adapted mobile app for Black adults with Cannabis Use Disorder
MASP 3.0
PI: Obasi; Project MPIs: Businelle & Zvolensky
​
The aim of this two phase study (Phase 1 n=24; Phase 2 n=200) is to refine and evaluate an initially developed and tested, novel, mobile intervention that targets sensitivity to bodily sensations among African American smokers and bridges the gap in access to care which has plagued this health disparities population. Data collection for phase 2 began in March 2023.
​
Smart-T Mental Health
PIs: Michael Businelle and Adam Alexander
​
This pilot randomized controlled trial (N=75) will evaluate the feasibility of an innovative, evidence-based smoking cessation app tailored for smokers with serious mental illness (SMI). Data collection is ongoing (current n=24).
​
OKquit
PI: Michael Businelle
​
This study (N=500) is a randomized controlled trial that will evaluate the feasibility and initial efficacy of an innovative, evidence-based smoking cessation app tailored for smokers that contact the Oklahoma Tobacco Helpline for services. Data collection is ongoing (current n=158).
​
MASP+
PI: Obasi; Project MPIs: Businelle & Garey
​
We will adapt our already developed and preliminarily tested, culturally adapted, mHealth smoking cessation intervention for Black smokers (MASP) to incorporate HIV disease management skills that are uniquely applicable to Black adults with HIV (MASP+).
Completed Projects
EASE
PIs: Michael Businelle and Michael Zvolensky
​
Utilizing a precision medicine approach, the Easing Anxiety Sensitivity for Everyone (EASE) app targets anxiety sensitivity, a transdiagnostic individual difference factor implicated in the etiology, maintenance, and progression of anxiety and depressive symptoms. EASE includes COVID-19 symptom monitoring, exposure management skills, and psychoeducation on COVID-19-related stress and the impact of stress on susceptibility to infection and disease progression. Participants (N=800; 200 Black, 200 Latinx, 200 American Indian, and 200 NLW) are randomized to either EASE or to an active standard-of-care control digital intervention for anxiety and depression. Study enrollment (N=824) completed in June 2023.
Smart-T 3 (R01CA221819)
PIs: Michael Businelle
This NCI R01 randomized clinical trial (N=450) compares the longer-term effects of the Smart-T smoking cessation app (see above app screenshot) with the free and publicly available NCI QuitGuide smoking cessation app (Aim 1). The second aim of the proposed study will determine if Smart-T messages that are tailored to address key smoking lapse risk variables in real-time (i.e., urge, stress, cigarette availability, cessation motivation) reduce participant ratings of these lapse risk variables compared with similar situations that do not receive this tailored content (QuitGuide group). Study enrollment completed in May 2023 (N=454).
Persist
PI: Michael Businelle & Rachel Funk-Lawler
This pilot randomized controlled trial (N=60) will assess the initial feasibility of a phone-delivered intervention for anxiety and depressive symptoms among cancer patients that are receiving active radiation treatments. Study enrollment completed during Summer 2023 (current n=57).
​
Link2Care
PIs: Michael Businelle & Jennifer Reingle Gonzalez
This 3-armed NIH R01 is a randomized controlled trial uses an innovative smartphone application to identify and address barriers that prevent recently incarcerated homeless adults from obtaining available case management, crisis management, substance abuse, and mental health services. Study enrollment (N=406) completed in November 2022.
Exemplar
PIs: Michael Businelle and Emily Hébert
​
The purpose of the 32 group MOST design is to identify the optimal components, or combinations of components, for achieving the highest compliance rates for smartphone-based ecological momentary assessments (EMAs). A total of 485 participants were enrolled nationwide over an 11 month study period.
Phoenix
PI: Michael Businelle
​
This pilot study (N = 152) was a 3-armed randomized controlled smoking cessation induction trial that examined the initial utility of two novel smartphone based interventions compared with an attention control group among smokers who were not ready to quit at baseline.
Symptom Tracker
PI: Michael Businelle & Katherine Moxley
The Symptom Tracker study (N=128) enrolled Stephenson Cancer Center patients during chemotherapy infusion visits. The Symptom Tracker app monitored symptoms (daily for 24 weeks) that were consistent with early signs of SARS-CoV-2 infection and automatically (and securely) transferred this information to health care providers. The primary aim of this study was to determine the feasibility, ease of use, and perceived utility of this app to monitor symptoms and health risk behaviors among cancer patients currently receiving chemotherapy.
​
Smart-T Alcohol
PIs: Michael Businelle & Scott Walters
​
This 2 phase NIH Funded R34 (N=41) developed and tested a “just in time” adaptive intervention to reduce alcohol use in homeless men and women. Phase I utilized smartphones and passive sensing technologies to monitor geolocation, psychosocial variables (e.g., stress, affect, urge to drink), and alcohol use (SCRAM). Phase II used this information to provide tailored treatment messages that anticipated and intervened to prevent drinking and heavy drinking.
Smoking Cessation for American Indians with Diabetes
​Investigators: Jennifer Vidrine, Darla Kendzor, Damon Vidrine, Michael Businelle
The purpose of this pilot study is to identify factors that predict smoking lapse among smokers who attend a Choctaw Nation Hospital Diabetes Clinic.
Smart-T2
PI: Michael Businelle
The primary objective of this research (N=81) was to reduce smoking relapse through the use of automated mobile smoking cessation interventions that tailor content in real-time based upon currently present symptoms. The primary short-term objective of this pilot study was to determine the initial utility of a novel smartphone based smoking cessation intervention compared with standard in-person smoking cessation clinic care and a free smoking cessation application.
Anxiety Sensitivity: M-ICART
PIs: Michael Businelle, Michael Zvolensky, & Julia Buckner
The purpose of this pilot project is to translate our previously tested Integrated Cannabis and Anxiety Reduction Treatment [ICART] into a novel, mobile intervention for Cannabis Use Disorders.
Anxiety Sensitivity: MASP
PIs: Michael Businelle & Michael Zvolensky
The purpose of this pilot study is to feasibility test a novel, mobile intervention for smokers with high anxiety sensitivity (AS). This Mobile Anxiety Sensitivity Program for Smoking (MASP) integrates interoceptive exposure, emotion regulation, cognitive restructuring, and psychoeducation exercises developed from our past work in conjunction with standard smoking cessation strategies and nicotine replacement therapy.
​Advance II
PI: Michael Businelle
The primary objective of this study is to gain a better understanding of the prevalence of physical and mental health issues among homeless adults in Oklahoma City. The secondary objective is to identify risk and protective factors that have an impact on health behavior and health behavior change in this understudied and underserved population. This information will improve understanding of the health needs of this marginalized group and will provide guidance to our future intervention work with homeless Oklahomans.
​Advance
PI: Michael Businelle
The primary objective of this project was to examine homeless individuals’ attitudes and beliefs about partial and full smoking bans at a local shelter before and after a partial smoking ban is implemented and to examine the short-term consequences of this ban. The secondary objective of this study was to determine the prevalence of modifiable cancer risk factors among a sample of homeless individuals.
Smart-T
PIs: Michael Businelle & Darla Kendzor
​
This study will determine if low SES increases the odds of relapse through a number of hypothesized mechanisms. This work is innovative because it will explore mediational pathways between SES and smoking cessation among individuals of varying racial/ethnic backgrounds from two distinct samples, using both traditional (questionnaire) and state-of-the-science real-time assessment methodology. This information was used to develop a new smart phone–based smoking cessation treatment that assesses relapse risk in real time and automatically intervenes to reduce risk.
Prevail
PIs: Michael Businelle & Darla Kendzor
​
The primary objectives of this study were: 1) to evaluate the efficacy of an adjunctive contingency management intervention for smokers of low socioeconomic status participating in a smoking cessation program at an urban safety net clinic (Parkland Tobacco Cessation Clinic), and 2) to identify barriers to smoking cessation and predictors of relapse in this population.
Aspire
PI: Michael Businelle
The primary objectives of this pilot project were to: 1) determine if ecological momentary assessment (EMA) methodology could be used to identify predictors of and barriers to successful smoking cessation in treatment seeking homeless smokers, and 2) determine if an adjunctive contingency management treatment component (i.e., small financial incentives for biologically confirmed abstinence) would increase abstinence relative to usual care in this population.
CT-MICART
PI: Lorra Garey
​
The goal of this randomized interventional study (N=50) is to develop, pilot test, and refine a culturally adapted, mobile app (CT-MICART) aimed at Black adults with Cannabis Use Disorder. This population faces barriers to traditional in-person treatments and has an increased risk of severe cannabis use patterns. This study is currently actively enrolling participants with completion expected by December 2023.